Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare
- PMID: 32393611
- PMCID: PMC7223283
- DOI: 10.1136/bmjopen-2019-034195
Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare
Abstract
Objectives: To evaluate workshops delivered to citizen health advocates about financial conflicts of interest in healthcare, transparency databases which disclose industry payments in the USA and Australia and the pros and cons of advocacy groups accepting industry sponsorship.
Design: Thematic analysis of workshop participant recorded discussions, and pre, post and 3-month follow-up questionnaires on confidence and knowledge about financial conflicts of interest, transparency databases and the merits of advocacy organisations accepting industry sponsorship.
Participants and setting: 48 citizen health advocates participated in a half-day workshop, held in four Australian cities, which ended with a 1-hour recorded discussion. Participants were recruited with assistance from leading state-based health advocacy organisations.
Results: The thematic analysis of the recorded discussions revealed two major themes, (i) transparency and (ii) relationships with industry; and three minor themes: a lack of awareness about conflicts of interest and transparency, issues relating to trust and next steps in terms of potential reforms. In relation to transparency, participants felt strong support for transparency, strongly favouring the mandatory, extensive and accessible US Open Payments over the self-regulatory Australian model. Participants also noted that transparency had limitations, including the utility of disclosed information. In relation to industry sponsorship of advocacy groups, some participants expressed an openness to and support for accepting sponsorship, while many expressed a caution around potential downsides. Questionnaire results showed increases in both confidence and knowledge after the workshop, though only 23 of 48 participants returned the 3-month follow-up questionnaire.
Conclusions: Following a half-day workshop, citizen health advocates recruited by leading health advocacy organisations expressed strong support for tough transparency rules, and mixed feelings about advocacy groups accepting sponsorship from industry. Study limitations include a non-representative sample and a large drop-out at the 3-month post-workshop follow-up.
Keywords: ethics; health services administration; public health.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.JAMA Dermatol. 2019 Apr 1;155(4):460-464. doi: 10.1001/jamadermatol.2018.5102. JAMA Dermatol. 2019. PMID: 30698625 Free PMC article.
-
Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.BMJ Open. 2019 Feb 19;9(2):e024928. doi: 10.1136/bmjopen-2018-024928. BMJ Open. 2019. PMID: 30782921 Free PMC article.
-
How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study.Aust Health Rev. 2019 Aug;43(4):474-480. doi: 10.1071/AH17288. Aust Health Rev. 2019. PMID: 30021681
-
Industry payments to authors of Journal of Shoulder and Elbow Surgery shoulder arthroplasty manuscripts are accurately disclosed by most authors and are not significantly associated with better reported treatment outcomes.J Shoulder Elbow Surg. 2020 Apr;29(4):667-673. doi: 10.1016/j.jse.2019.09.045. Epub 2019 Dec 30. J Shoulder Elbow Surg. 2020. PMID: 31899091
-
Decoding disclosure: Comparing conflict of interest policy among the United States, France, and Australia.Health Policy. 2018 May;122(5):509-518. doi: 10.1016/j.healthpol.2018.03.015. Epub 2018 Mar 21. Health Policy. 2018. PMID: 29605526 Review.
Cited by
-
Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis.BMJ Open. 2023 Mar 29;13(3):e061591. doi: 10.1136/bmjopen-2022-061591. BMJ Open. 2023. PMID: 36990486 Free PMC article.
-
"I never thought of it as payment": Qualitative evaluation of workshops with advanced practice registered nurses on pharmaceutical industry payment reporting.J Am Assoc Nurse Pract. 2025 Jan 1;37(1):51-60. doi: 10.1097/JXX.0000000000001077. J Am Assoc Nurse Pract. 2025. PMID: 39392645 Free PMC article.
-
Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians.Int J Environ Res Public Health. 2022 Mar 15;19(6):3478. doi: 10.3390/ijerph19063478. Int J Environ Res Public Health. 2022. PMID: 35329160 Free PMC article.
-
Commercial influences on patient and public involvement: a renewed call for research and action.Health Promot Int. 2024 Dec 1;39(6):daae188. doi: 10.1093/heapro/daae188. Health Promot Int. 2024. PMID: 39657731 Free PMC article.
References
-
- Institute of Medicine Committee on conflict of interest in medical research, education, and practice : Lo B, Field MJ, Conflict of interest in medical research, education, and practice: summary. Washington, DC: National Academies Press, 2009. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous